Literature DB >> 21732897

Acceptance-based behavior therapy to promote HIV medication adherence.

Ethan Moitra1, James D Herbert, Evan M Forman.   

Abstract

A significant number of adults with HIV in the USA do not maintain adherence to highly active antiretroviral therapy (HAART) at adequate levels. Although traditional cognitive behavioral interventions have shown promise in promoting HAART adherence, acceptance-based behavior therapy (ABBT) may be particularly useful in this population. ABBT has the potential to overcome common avoidance-based barriers associated with poor adherence, including denial of various illness-related factors and avoidance of stigmatization. We describe the rationale for promoting psychological and behavioral acceptance in HIV-positive populations; outline an ABBT to promote HAART adherence targeting primary care patients from urban, minority, low socioeconomic backgrounds; and report preliminary qualitative observations of treatment feasibility and acceptability.

Entities:  

Mesh:

Year:  2011        PMID: 21732897     DOI: 10.1080/09540121.2011.579945

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  19 in total

1.  Distress tolerance and use of antiretroviral therapy among HIV-infected individuals in substance abuse treatment.

Authors:  Jessica F Magidson; C J Seitz-Brown; Alyson Listhaus; Briana Lindberg; Katelyn E Anderson; Stacey B Daughters
Journal:  AIDS Patient Care STDS       Date:  2013-09       Impact factor: 5.078

2.  Buffering Internalization of HIV Stigma: Implications for Treatment Adherence and Depression.

Authors:  Bulent Turan; Kaylee B Crockett; Asuman Buyukcan-Tetik; Mirjam-Colette Kempf; Deborah Konkle-Parker; Tracey E Wilson; Phyllis C Tien; Gina Wingood; Torsten B Neilands; Mallory O Johnson; Sheri D Weiser; Janet M Turan
Journal:  J Acquir Immune Defic Syndr       Date:  2019-03-01       Impact factor: 3.731

3.  Acceptance and Commitment Therapy (ACT) for HIV-infected Hazardous Drinkers: A Qualitative Study of Acceptability.

Authors:  Sarah E Woolf-King; Alan Z Sheinfil; Jacklyn D Babowich; Bob Siedle-Khan; Amanda Loitsch; Stephen A Maisto
Journal:  Alcohol Treat Q       Date:  2018-11-08

4.  Non-planning Impulsivity But Not Behavioral Impulsivity is Associated with HIV Medication Non-adherence.

Authors:  Eugene M Dunne; Robert L Cook; Nicole Ennis
Journal:  AIDS Behav       Date:  2019-05

5.  Development of a coping intervention to improve traumatic stress and HIV care engagement among South African women with sexual trauma histories.

Authors:  Kathleen J Sikkema; Karmel W Choi; Corne Robertson; Brandon A Knettel; Nonceba Ciya; Elizabeth T Knippler; Melissa H Watt; John A Joska
Journal:  Eval Program Plann       Date:  2018-03-06

Review 6.  Cultural relevance in medication adherence interventions with underrepresented adults: systematic review and meta-analysis of outcomes.

Authors:  Vicki S Conn; Maithe Enriquez; Todd M Ruppar; Keith C Chan
Journal:  Prev Med       Date:  2014-10-28       Impact factor: 4.018

7.  Open Trial of an Acceptance-Based Behavior Therapy Intervention to Engage Newly Diagnosed HIV Patients in Care: Rationale and Evidence of Feasibility and Acceptability.

Authors:  Ethan Moitra; Philip A Chan; Michael D Stein
Journal:  Behav Modif       Date:  2015-06-25

Review 8.  Medication adherence interventions that target subjects with adherence problems: Systematic review and meta-analysis.

Authors:  Vicki S Conn; Todd M Ruppar; Maithe Enriquez; Pam Cooper
Journal:  Res Social Adm Pharm       Date:  2015-06-15

9.  The application of mindfulness for individuals living with HIV in South Africa: A hybrid effectiveness-implementation pilot study.

Authors:  Tracy-Leigh McIntyre; Diane Elkonin; Margo de Kooker; Jessica F Magidson
Journal:  Mindfulness (N Y)       Date:  2017-10-10

Review 10.  Patient-Centered Outcomes of Medication Adherence Interventions: Systematic Review and Meta-Analysis.

Authors:  Vicki S Conn; Todd M Ruppar; Maithe Enriquez; Pamela S Cooper
Journal:  Value Health       Date:  2016-01-14       Impact factor: 5.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.